A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia

This is a prospective, multicenter, phase Ⅱ study consisting of dose escalation and ex-pansion stages in unfit newly diagnosed AML.

Trial Details

NCT ID
NCT07743112
Phase
PHASE2
Sponsor
Maxinovel Pty., Ltd.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • MAX-40279
  • Azacitidine
  • Venetoclax
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • 1\. Patients meeting the World Health Organization (WHO) 2016 diagnostic criteria for newly diagnosed acute myeloid leukemia (AML) patients unfit f…
  • Age ≥65 years, or
  • Age \>18 years and ineligible for standard-dose chemotherapy, defined by ≥1 of the following:
  • ECOG performance status 2 or 3;History of chronic heart failure (CHF) requiring treatment or left ventricular ejection fraction (LVEF) ≤50% DLCO ≤6…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →